NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report released on Monday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets reduced their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Up 4.7 %

NYSE:NBY opened at $0.73 on Monday. The stock’s 50 day moving average price is $0.62 and its 200 day moving average price is $0.77. The company has a market capitalization of $3.60 million, a PE ratio of -0.01 and a beta of 0.65. NovaBay Pharmaceuticals has a 52-week low of $0.36 and a 52-week high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.